Cure My Disease

Don't miss your cure!

 Log in / Sign up

A drug used during liver surgery may cut the risk of major complications — a study puts it to the test

NCT ID NCT07719933

Disease control Sponsor: First Affiliated Hospital, Sun Yat-Sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 29, 2026 · Updated 3 times

Summary

This study looks at whether giving a drug called terlipressin continuously during keyhole (laparoscopic) liver surgery can lower the chance of severe complications afterward. Terlipressin helps keep blood pressure stable, which may protect organs during surgery. Researchers will follow about 160 adults having liver tumor surgery and compare those who received the drug with those who did not.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
terlipressin, a drug that helps maintain blood pressure during surgery
What this could lead to
If it works, this could point toward a simple way to lower the risk of severe complications after liver surgery.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by other factors. The drug may also have side effects like reduced blood flow to organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

161 people

The number who actually took part.

Started

Apr 2024

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients who undergo laparoscopic hepatectomy for liver diseases at the First Affiliated Hospital of Sun Yat-sen University. Eligible patients will be prospectively enrolled according to predefined criteria and followed throughout the perioperative period. Clinical characteristics, intraoperative management, terlipressin exposure, and postoperative outcomes will be collected and analyzed.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 80 years * American Society of Anesthesiologists (ASA) physical status I-III * Scheduled for elective laparoscopic partial hepatectomy * Provided written informed consent Exclusion Criteria: * Inability to tolerate the planned surgical procedure based on pre-anesthetic assessment * Severe hepatic dysfunction (Child-Pugh class B or higher) * Severe renal dysfunction (blood urea nitrogen \> 9 mmol/L or serum creatinine \> 178 μmol/L) * Significant cardiovascular or cerebrovascular disease, including active coronary artery disease, severe valvular stenosis, hypertrophic obstructive cardiomyopathy, or history of extensive cerebral infarction * Known allergy to study medications * Body mass index (BMI) \> 35 kg/m² or \< 18 kg/m² * Hemoglobin level \< 90 g/L * Pregnancy or lactation * Participation in another clinical trial within the preceding 3 months * Any other condition considered inappropriate for study participation by the investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver neoplasms are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver and intrahepatic bile duct neoplasm Liver Neoplasms Pleural Effusion Postoperative Complications

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver neoplasms Postoperative complications

Contacts and locations

Locations

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510080, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.